MolecuLight's Fluorescence Imaging: A Game-Changer for Bedside Biofilm Detection

MolecuLight Inc. Ontario

is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

Photo - https://mma.prnewswire.com/media/2532654/MolecuLight_MolecuLight_s_Fluorescence_Imaging__A_Game_Changer_f.jpg

View original content:https://www.prnewswire.co.uk/news-releases/moleculights-fluorescence-imaging-a-game-changer-for-bedside-biofilm-detection-302278727.html